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Rapid communications
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We describe a multidrug-resistant  Neisseria gonor-
rhoeae  infection with ceftriaxone resistance and 
azithromycin intermediate resistance in a heterosexual 
man in Denmark, 2017. Whole genome sequencing of 
the strain GK124 identified MSLT ST1903, NG-MAST 
ST1614 and all relevant resistance determinants 
including similar penA resistance mutations previ-
ously described in ceftriaxone-resistant gonococcal 
strains. Although treatment with ceftriaxone 0.5 g plus 
azithromycin 2 g was successful, increased awareness 
of spread of gonococcal strains threatening the recom-
mended dual therapy is crucial.
In the last decade, high-level resistance to extended-
spectrum cephalosporins (ESCs) has been reported 
in  Neisseria gonorrhoeae  worldwide, leading to 
treatment failures with oral cefixime and the more 
potent injectable ceftriaxone [1-10]. The emergence 
of ESC resistance has caused public health concern 
worldwide [9,11-13] and dual antimicrobial therapy is 
now recommended as the first-line empirical treatment 
of uncomplicated gonorrhoea in parts of the world 
including Europe [8,14]. It is worrying that failure to 
treat pharyngeal gonorrhoea with dual antimicrobial 
therapy was recently verified in the United Kingdom 
[15]. Fortunately, ceftriaxone resistance remains rare in 
Europe [16].
This report describes one rare case of a multid-
rug-resistant (MDR)  N. gonorrhoeae  infection with 
ceftriaxone resistance and intermediate resistance to 
azithromycin, detected in Denmark in 2017.
Case description
A heterosexual man in his 20s from Denmark pre-
sented at a general practitioner clinic in Copenhagen, 
Denmark in January, 2017 with urethritis symptoms that 
he had had for two days. He had had three unprotected 
sexual relations with women (of Danish, Chinese and 
Australian nationality) during the previous 6 months 
and he had not travelled abroad during that time. He 
was empirically treated unsuccessfully with a single 
oral dose of azithromycin 1 g because non-gonococ-
cal urethritis was suspected. A nucleic acid amplifi-
cation test (NAAT) (Aptima Combo 2, Hologic Inc.) of 
urine sampled at the visit to the general practitioner 
clinic, was positive for N. gonorrhoeae and the patient 
was referred 6 days later to the sexually transmitted 
diseases (STD) clinic with urethritis symptoms without 
purulent discharge. Culture from a urethral swab (eight 
days after symptom onset) was positive for  N. gonor-
rhoeae, while NAAT and culture of pharyngeal and 
rectal samples were negative. He was successfully 
treated with single doses of ceftriaxone 0.5 g intra-
muscularly and azithromycin 2 g orally and advised to 
abstain from sexual contacts until test-of-cure (TOC) 
as outlined in the Danish treatment recommendation 
[17]. Two weeks after treatment, the TOC using NAAT 
of urethral and pharyngeal samples were negative and 
all symptoms were resolved. The patient had no sexual 
contacts between onset of symptoms and TOC. The 
Danish sexual contact was NAAT-negative and the two 
other women were lost to follow-up.
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Characterisation of the Neisseria 
gonorrhoeae isolate 
Minimum inhibitory concentration (MIC) values for 
ceftriaxone, cefixime, azithromycin, spectinomycin, 
ciprofloxacin, and benzylpenicillin in the  N. gonor-
rhoeae  strain isolated from the patient, GK124, were 
determined in duplicate using Etest (bioMerieux, 
Ballerup, Denmark) and results were interpreted 
in accordance with the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) interpre-
tative criteria [18]. GK124 showed resistance to ceftri-
axone (MIC: 0.25–0.5 mg/L), cefixime (MIC: 1 mg/L), 
ciprofloxacin (MIC: > 32 mg/L) and benzylpenicil-
lin (MIC: > 256 mg/L), and intermediate resistance to 
azithromycin (MIC: 0.5 mg/L). GK124 was susceptible 
to spectinomycin (MIC: 8 mg/L) (Table).
Whole genome sequencing (WGS) was performed 
on an Illumina MiSeq as previously described [19]. 
The GK124 genome was compared with previously 
described ceftriaxone-resistant strains (WHO X (H041), 
WHO Y (F89), WHO Z (A8806) [1,2,5,20] and FC428 [7]) 
using ResFinder 3.0, an update of ResFinder focusing 
on chromosomal mutational resistance (cge.cbs.dtu.
dk/services/ResFinder/version 3.0) and previous pub-
lications (Table). Based on the WGS sequence, the 
sequence type (ST) of GK124 was ST1903 as derived 
by multilocus sequence typing (MLST) and ST1614 as 
derived by  N. gonorrhoeae  multi-antigen sequence 
typing (NG-MAST) (Table). The draft genome of GK124 
can be found under GenBank accession number: 
PRJEB22246.
Regarding ESC resistance determinants, GK124 con-
tained the amino acid alterations A311V, I312M, V316T, 
T483S and G545S, which indicated that the strain had a 
mosaic penA allele as well as additional key ceftriaxone 
resistance mutations [4,5,7,13,20]. Furthermore, the 
strain contained G120K and A121D alterations in PorB1b 
and the A-deletion in the inverted repeat sequence 
of the  mtrR  promoter region that further increase the 
ESC MICs and contribute to the MDR characteristics 
of GK124. No mutations associated with azithromycin 
resistance were found in the 23S rRNA gene and, 
accordingly, the intermediate resistance to azithro-
mycin was due to the  mtrR  resistance determinant 
and possibly additional unknown mutations. SNPs 
in  gyrA  (S91F, D95A), encoding the A subunit of the 
DNA gyrase, caused the high-level ciprofloxacin resist-
ance [4] (Table).
TABLE
Antibiotic resistance pattern, multidrug-resistant Neisseria gonorrhoeae patient isolate GK124, Denmark, 2017, compared 
with four whole-genome-sequenced ceftriaxone-resistant N. gonorrhoeae strains
Strain (year, country, 
name) 2017, Denmark, GK124
2015, Japan, FC428 
[7]
2013, Australia, A8806 
 
(WHO Z [2,20])
2010, France, F89 
 
(WHO Y [1,20])
2009, Japan, H041 
 
(WHO X [5,20])
Minimal inhibitory concentration [mg/La]
Ceftriaxone 0.25–0.5 0.5 0.5 1–2 2–4
Cefixime 1 1 ND 4 8
Azithromycin 0.5 0.25 0.25 1 1
Spectinomycin 8 8 ≤ 64 16 16
Ciprofloxacin > 32 > 32 >32 > 32 > 32
Benzylpenicillin > 256 > 32 1 1 4
Sequence type
MLST 1903 1903 7363 1901 7363
NG-MAST 1614 3435 4015 1407 4220
Key ceftriaxone resistance alterations in PBP2
Encoded by penA A311V, T483S (I312M, V316T, G545S)b
A311V, T483S 
(I312M, V316T, 
G545S)b
A311V, 
 
T483S (I312M, V316T, 
 
G545S)b
A501P (I312M, 
V316T, G545S)b
A311V, V316P, 
T483S (I312M, 
G545S)b
Other relevant resistance determinants
PorB1b G120K, A121D G120K, A121D G120K, A121D G120K, A121N G120K, A121D
mtr locus A-del A-del ND A-del A-del
GyrA S91F, D95A ND S91F, D95N S91F, D95G S91F, D95N
MIC: minimum inhibitory concentration; MLST: multilocus sequence typing; ND: not described; NG-MAST: N. gonorrhoeae multi-antigen 
sequence typing; PBP2: penicillin-binding protein 2; WHO: World Health Organization reference strain.
a Only whole MIC doubling dilutions are reported.
b Mutations in the parenthesis indicate a mosaic penA allele.
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Discussion
This report describes one rare case of MDR  N. gon-
orrhoeae  infection with ceftriaxone resistance and 
intermediate resistance to azithromycin in Denmark, 
2017. This case was reported by the national healthcare 
authorities but has not lead to wider public health 
actions [21]. Increased awareness of the spread of 
this type of gonococcal strains that threaten the rec-
ommended dual antimicrobial therapy is crucial. This 
is especially important when the incidence of gonor-
rhoea is rapidly increasing in many countries, including 
in Denmark where a sevenfold increase in the gonor-
rhoea incidence was observed from 2011 to 2016 [21]. 
This increase in Denmark was not caused by increased 
awareness as the number of samples tested per year 
has increased by about 2% and dual testing for chla-
mydia and N. gonorrhoeae by NAAT is implemented in 
most of the country. Furthermore, dual antimicrobial 
therapy with ceftriaxone 500 mg plus azithromycin 2 g 
for empiric treatment of gonorrhoea is recommended 
in Europe [14]; however, the level of implementation 
of this dual therapy is unknown and several countries 
still recommend monotherapy with ceftriaxone [22] and 
even other antimicrobials such as azithromycin.
The MLST ST of GK124, ST1903, has previously been 
described in the ceftriaxone-resistant strain FC428 
isolated in 2015 in Japan [7], but the NG-MAST ST1614 
has not been previously associated with ceftriaxone 
resistance. GK124 contained several key ESC resist-
ance mutations in  penA: I312M, V316T, G545S, which 
are indicator mutations for a mosaic  penA  allele, and 
also two (A311V, T483S) of the three key ceftriaxone 
resistance mutations in the pan-resistant H041 (WHO 
X) [5,13,20]. These mutations have also been found 
in most of the ceftriaxone-resistant strains character-
ised in detail [2,5,7,20]. This provides further evidence 
that both ceftriaxone-resistant strains and ceftriax-
one resistance-determining PBP2 sequences might be 
spreading internationally [7].
Conclusion
An MDR  N. gonorrhoeae  strain with ceftriaxone 
resistance and intermediate resistance to azithromycin 
was found in Denmark in 2017. Our patient only had 
genital infection and was cured by dual antimicrobial 
therapy. Increased awareness of the spread of this 
type of gonococcal strains, improved implementation 
of the recommended dual antimicrobial therapy (for all 
patients and not only for high-risk populations), part-
ner notification, TOC and appropriate verification/fal-
sification of suspected treatment failures are crucial 
internationally as the recommended dual antimicro-
bial therapy is threatened. Ultimately, novel treatment 
options for gonorrhoea and ideally an effective gono-
coccal vaccine are imperative.
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